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Abstract 
Prospective DPYD genotyping prevents severe fluoropyrimidine-induced toxicity by decreasing 
dosages in DPYD variant allele carriers. Fluoropyrimidine dosages in chemoradiation therapy (CRT) 
are lower compared to other fluoropyrimidine-containing regimens. Pharmacogenetic guidelines do 
not distinguish between regimens, leaving physicians in doubt to apply dose reductions. Our aim was 
to investigate severe toxicity in DPYD variant allele carriers receiving CRT. 
Medical records of 828 patients who received fluoropyrimidine-based CRT were reviewed 
from three centers. Severe (grade ≥3) toxicity in DPYD variant allele carriers receiving upfront 
fluoropyrimidine dose reductions according to pharmacogenetic dosing guidelines and DPYD variant 
allele carriers not receiving fluoropyrimidine dose reductions was compared with DPYD wild-type 
patients receiving standard dose of fluoropyrimidines in CRT.  
DPYD variant allele carriers treated with standard dosages (N=34) showed an increased risk 
of severe gastrointestinal (adjusted OR: 2.58, 95% confidence interval [95%CI]: 1.02─6.53, p=0.045) 
or severe haematological (adjusted OR: 4.19, 95%CI: 1.32─13.25, p=0.015) toxicity compared with 
wild-type patients (N=771). DPYD variant allele carriers who received dose reductions (N=22) 
showed a comparable frequency of severe gastrointestinal toxicity compared with wild-type 
patients, but more (not statistically significant) severe haematological toxicity. Hospitalisations for all 
DPYD variant allele carriers were comparable, independent of dose adjustments; however, the mean 
duration of hospitalisation was significantly shorter in the dose reduction group (p=0.010).  
Standard fluoropyrimidine dosages in CRT resulted in an increased risk of severe toxicity in 
DPYD variant allele carriers. We advise to apply fluoropyrimidine dose reductions according to 
current guidelines in DPYD variant allele carriers starting CRT. 
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Introduction 
Fluoropyrimidines, such as 5-fluorouracil (5-FU) and capecitabine, are the backbone of 
chemotherapy regimens for solid tumours such as colorectal and breast cancer.1-3 Since the 90’s, 5-
FU has been in use in neoadjuvant chemoradiation therapy (CRT) for patients with stages 2-3 rectal 
cancer.4,5 Fluoropyrimidines affect nucleotide metabolism and inhibit the repair of radiation-induced 
DNA damage in patients and act as a radiation sensitiser.6 Fluoropyrimidines in combination with 
radiotherapy are used at lower dosages than those in other treatment regimens. An example; for 
patients with advanced colorectal cancer capecitabine, dosages are usually 1,250 mg/m2 bid (twice 
daily) for two weeks followed by one week rest, repeated every three weeks.7 In combination with 
radiotherapy, a continuous regimen is preferred to optimise radio-sensitisation. The maximum 
tolerated dose of capecitabine was 825 mg/m2 bid for patients with rectal cancer.8,9  
 
Adverse events are well known in fluoropyrimidine treatment and differ between treatment 
regimens. Severe (grade ≥3) side-effects in stage 3 or 4 colorectal cancer patients treated with 
capecitabine monotherapy dosed 1,250 mg/m2 bid in three-week cycles, were hand-foot syndrome 
(~18%), diarrhoea (~14%), stomatitis (~3%), vomiting (~3%) and neutropenia (~3%).10-12 Severe side-
effects in locally advanced rectal cancer patients treated with CRT, including 825 mg/m2 
capecitabine continuously for five weeks, were grade ≥3 radiation dermatitis (~9%), diarrhoea (~2-
7%), fatigue (~2%), neutropenia (~2%) and anaemia (~2%).13,14 
 
Over 80% of 5-FU is degraded into inactive metabolites by the key enzyme dihydropyrimidine 
dehydrogenase (DPD).15 DPD is encoded by the gene DPYD. DPD and variants in DPYD are associated 
with the onset of severe fluoropyrimidine-induced toxicity. To prevent severe fluoropyrimidine-
induced toxicity prospective DPYD genotyping is increasingly used in clinical practice, followed by 
dose reductions in patients who carry a DPYD variant. For four variants (DPYD*2A, c.1905+1G>A, 
rs3918290; DPYD*13, c.1679T>G, rs55886062; c2846A>T, rs67376798; c.1236G>A/HapB3, 
rs56038477) individual dosing guidelines are currently given by the Dutch Pharmacogenetics 
Working Group and Clinical Pharmacogenetics Implementation Consortium.16,17 Dosing guidelines 
advise that DPYD variant allele carriers should receive a percentage of the standard dose, for 
example 50 or 75%, depending on the specific variant.18 These guidelines do not distinguish between 
treatment regimens in which different fluoropyrimidine dosages are given. Because fluoropyrimidine 
dosages in CRT regimens are lower than those in other treatment regimens, it is questioned if dose 
adjustments in dosing guidelines should be applied in patients receiving fluoropyrimidines in CRT. 
The objective of this study was to investigate the frequency of severe treatment-related toxicity in 
DPYD variant allele carriers receiving reduced or standard fluoropyrimidine dosages in CRT, to 
determine whether dose reductions are required. 
 
Methods 
Study population 
The study population consisted of three combined databases. All patients were treated with 
fluoropyrimidine-based CRT according to the various tumour types and were genotyped for the 
aforementioned four variants in DPYD.  
 
At the Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands, a prospective clinical trial 
was executed in which patients were prospectively genotyped for DPYD*2A followed by dose 
 
 
reductions of ≥50% in DPYD*2A carriers (NCT00838370).19 The trial was approved by the institutional 
review board (IRB) of all participating institutes, and all DPYD*2A carriers provided written informed 
consent before study registration. The patients were retrospectively genotyped for the three other 
variants (DPYD*13, c.2846A>T, c.1236G>A). A total of 497 patients received CRT and were selected 
for the present study. Two patients had missing genotypes and were excluded. Radiation dose in 
Gray (Gy) and fractions (Fr) given to the patient could be collected retrospectively for 425 patients.  
At Leiden University Medical Center (LUMC), Leiden, the Netherlands, a retrospective database was 
created for the purpose of this study. The study was reviewed and approved by the IRB. All patients 
scheduled to start fluoropyrimidine-based CRT between April 2013 and September 2017 were 
evaluated. In total, 253 patients started therapy. In April 2013, only DPYD*2A was genotyped; 
DPYD*13 and c.2846A>T were added to the genotyping panel in October, and c.1236G>A was added 
in May 2014. Some patients were prospectively genotyped for DPYD*2A alone (N=20) or DPYD*2A, 
DPYD*13 and c.2846A>T (N=35). Missing genotypes were determined retrospectively. Thirteen 
patients could not be genotyped and were excluded. Data were collected from the electronic patient 
files. Ten percent of the data was checked by an independent data manager. Ten percent of toxicity 
data was checked by an oncologist and radiation oncologist. Limited discrepancies were discussed 
and similar errors were searched and corrected.  
At CRO-Aviano National Cancer Institute, Northern Italy, 207 patients were enrolled in a study from 
December 1993 to April 2016. All procedures were reviewed and approved by the IRB and patients 
signed written informed consent for research purposes. Ninety-five patients were included in the 
present study of whom additional chemotherapy treatment details could be collected. Sixteen 
patients were prospectively tested for DPYD*2A, DPYD*13 and c.2846A>T, and 79 patients were 
tested after start of treatment. Missing genotypes of c.1236G>A were determined retrospectively. 
Two patients had incomplete genotype data and were excluded.   
Groups 
All included patients in the combined database were grouped into wild-types receiving standard 
fluoropyrimidine dosages in CRT, DPYD variant allele carriers receiving standard fluoropyrimidine 
dosages in CRT or DPYD variant allele carriers receiving upfront reduced fluoropyrimidine dosages in 
CRT. DPYD variant allele carriers are heterozygous or homozygous for a DPYD variant (DPYD*2A, 
DPYD*13, c.2846A>T or c.1236G>A). Initial dose reductions (25 or 50%) were applied corresponding 
to pharmacogenetic guidelines.16,17 
 
Toxicity 
Treatment-related toxicity data were scored prospectively according to the National Cancer Institute 
common terminology criteria for adverse events (CTC-AE) v3.020 for the NKI and CRO databases, and 
retrospectively using CTC-AE v4.0321 for the LUMC database. It was not possible to determine 
missing toxicities retrospectively. In CRT a continuous regimen is used, and there are no cycles; 
therefore, the highest toxicity grade over the entire treatment period was used. Gastrointestinal 
toxicity included diarrhoea, mucositis, nausea and vomiting (nausea or vomiting were not scored by 
all databases). Haematological toxicity included leukopenia, thrombocytopenia and neutropenia.  
Statistics 
To study the association between study groups and severe gastrointestinal or haematological 
 
 
toxicity multivariable logistic regression models with grouped diagnosis as covariate were estimated. 
Gastrointestinal and haematological toxicity outcomes were dichotomised (grades 0─2 versus grades 
3─5). Diagnoses were grouped according to tumour location, either pelvic or non-pelvic region 
(grouped diagnosis). Differences in baseline characteristics between study groups were tested using 
Pearson Chi-square or Kruskal Wallis tests. Owing to the retrospective character of this study, there 
was no protocol on how to deal with additional dose adjustments during treatment in the analysis. A 
Mann–Whitney U test was applied to compare duration of hospitalisation between DPYD variant 
allele carriers who received dose reductions or standard dosages. P-values of <0.05 were considered 
statistically significant. Statistical analyses were performed using SPSS (v23, Chicago, IL, USA). 
Results 
Study population 
The combined database of 828 patients was divided into three study groups. Seven hundred 
seventy-one patients were wild-types, 34 patients were DPYD variant allele carriers who received 
standard fluoropyrimidine dosages in CRT and 23 patients were DPYD variant allele carriers who 
received upfront reduced (50 or 75%) fluoropyrimidine dosages in CRT. Baseline characteristics per 
database and study group are shown in Tables 1 and 2. Each original database included patients in 
each study group, described in Table 2. Cancer of the rectum was the most present in 71.7% of the 
patients. 86.6% of the patients received capecitabine. Baseline characteristics between study groups 
showed no significant differences.  
 
In one DPYD *2A carrier, dose reductions were applied during treatment but not at the first drug 
administration. In three DPYD*2A carriers initial reduced dosages were increased during treatment. 
Three out of four patients had a total dose intensity of approximately 50% (according to current 
dosing guidelines). The fourth patient was excluded from statistical analyses. These four patients 
were described in Table 2. 
 
Toxicity 
Toxicity of patients from this study treated with comparable treatment schedules was similar to 
toxicity of rectal cancer patients described in literature (Supplementary Table 1). Differences in 
toxicity between databases were observed. Grade 2 radiation dermatitis and grade 2 ‘other toxicity’ 
were very high in the LUMC and CRO database, respectively, resulting in a high overall toxicity 
percentage in these databases (Supplementary Table 2). Toxicity separated per study group is shown 
in Table 3.  
 
Percentages of severe gastrointestinal and haematological toxicity were 8 and 2.9% for wild-types, 
17.6 and 11.8% for DPYD variant allele carriers treated with a standard dose, and 9.1 and 9.1% for 
DPYD variant allele carriers who received a reduced dose, respectively (Figure 1, Table 3). DPYD 
variant allele carriers treated with a standard dose had a significantly increased risk to develop 
severe gastrointestinal toxicity (adjusted OR: 2.58, 95% confidence interval [95%CI]: 1.023─6.534, 
p=0.045) and severe haematological toxicity (adjusted OR:4.19, 95%CI: 1.323─13.253, p=0.015) 
compared with DPYD wild-type patients treated with standard dose. No statistical significant 
difference was found for the risk of developing severe gastrointestinal toxicity (adjusted OR: 1.10, 
95%CI: 0.250─4.804, p=0.904) or severe haematological toxicity (adjusted OR: 3.88, 95%CI: 
0.837─18.016, p=0.083) in DPYD variant allele carriers who received an initially reduced dose 
 
 
compared with wild-types. Grouped diagnosis was not significantly associated with the development of severe gastrointestinal toxicity (adjusted OR: 0.26, 
95%CI: 0.061─1.069), while it was for severe haematological toxicity (adjusted OR: 4.21, 95%CI: 1.760─10.053, p=0.001), with more toxicity in pelvic 
malignancies.  
 
Table 1. Baseline characteristics of patients from three original databases and of the combined database (total) 
Characteristics DB#1:NKI (N=495) 
N (%) 
DB#2:LUMC (N=240) 
N (%) 
DB#3:CRO (N=93) 
N (%) 
TOTAL (N=828) 
N (%) 
Sex, male 283 (57.2) 122 (50.8) 60 (64.5) 465 (56.2) 
Age, median [range] 62 [32─86] 65 [23─86] 63 [33─88] 63 [23─88] 
BSA, median [range] 1.9 [1.38─2.71] 1.89 [1.39─2.54] 1.85 [1.4─2.2] 1.9 [1.38─2.71] 
Diagnosis  
     Rectum cancer 
     Anus cancer 
     Vulva/vagina cancer 
     Pancreas cancer 
     Upper GI cancer 
     Other cancers 
 
344 (69.5) 
80 (16.2) 
1 (0.2) 
- 
54 (10.9) 
16 (3.2) 
 
157 (65.4) 
36 (15.0) 
17 (7.1) 
5 (2.1) 
10 (4.2) 
15 (6.3) 
 
93 (100) 
- 
- 
- 
- 
- 
 
594 (71.7) 
116 (14) 
18 (2.2) 
5 (0.6) 
64 (7.7) 
31 (3.7) 
Grouped diagnosis 
     Pelvic region cancera  
     Non-pelvic region cancerb  
     Other cancers 
  
432 (87.3) 
60 (12.1) 
3 (0.6) 
 
223 (92.9) 
17 (7.1) 
- 
 
93 (100) 
- 
- 
 
748 (90.7) 
77 (9.3) 
3 (0.4) 
Treatment type 
     Capecitabine 
     5-FU  
 
442 (89.3) 
53 (10.7) 
 
183 (76.3) 
57 (23.8) 
 
92 (98.9) 
1 (1.1) 
 
717 (86.6) 
111 (13.4) 
Treatment date [range] [01/2007─02/2012] [12/2012─09/2017] [04/2006─04/2016] [05/2006─09/2017] 
Radiotherapy 
     Gy: median [range] 
     Fr: median [range] 
 
50 [20─78]c  
25 [5─39]c 
 
50 [7.2─69.4] 
25 [4─38] 
 
55 [31.5─55.2] 
25 [15─28]d 
 
50 [7.2─78]c   
25 [4─39]e 
DPYD carriers total 
     DPYD*2A 
     DPYD*13 
     c.2846A>T 
     c.1236G>A 
     c.1236G>A homozygote  
36 (7.3) 
7 (1.4) 
1 (0.2) 
9 (1.8) 
17 (3.4) 
2 (0.4) 
18 (7.5) 
6 (2.5) 
- 
-  
12 (5) 
- 
3 (3.2) 
- 
- 
1 (1.1) 
2 (2.2) 
- 
57 (6.9) 
13 (1.6) 
1 (0.1) 
10 (1.2) 
31 (3.7) 
2 (0.2) 
 
 
a Included are cancers of the colon sigmoidal, rectum, anus, vulva, vagina, cervix, uterus, endometrium, 
bladder, urethra, prostate and double tumours with one tumour in the pelvic area; 
b Included are cancers of the breast, stomach, oesophagus, pancreas, skin, tongue; 
c Seventy-one patients have missing data; 
d One patient has missing data; 
e Seventy-two patients have missing data. 
Abbreviations: BSA: body surface area; CRO: Aviano National Cancer Institute; DB: database; DPYD: gene 
encoding dihydropyrimidine dehydrogenase; 5-FU: 5-fluorouracil; Fr: fractions; GI: gastro-intestinal tract; Gy: 
gray; LUMC: Leiden University Medical Center; NKI: Netherlands Cancer Institute. 
 
Table 2. Baseline characteristics per study group 
No significant differences between study groups in baseline characteristics were found. Differences in median 
dose intensity, treatment date and DPYD carriers were not tested. All original databases were able to include 
patients in each study group. Of the 34 DPYD variant allele carriers who received standard fluoropyrimidine 
dosages in CRT, 29 patients were included from NKI, three patients from LUMC (2x DPYD*2A, 1x c.1236G>A) 
and two c.1236G>A carriers from the CRO database. Of the 23 DPYD variant allele carriers who received 
upfront dose reductions in CRT, 15 patients were included from LUMC, seven DPYD*2A carriers from NKI and 
one c.2846A>T carrier from the CRO database.  
Characteristics WT + standarda  
(N=771) 
N (%) 
DPYD + standardb  
(N=34)  
N (%) 
DPYD + reducedc  
(N=23)  
N (%) 
Sex, male 432 (56) 20 (58.8) 13 (56.5) 
Age, median [range] 63 [23─88] 64 [45─79] 66 [50─78] 
BSA, median [range] 1.89 [1.38─2.71] 1.93 [1.51─2.34] 2 [1.50─2.44] 
Diagnosis 
     Rectum cancer 
     Anus cancer 
     Vulva/vagina cancer 
     Pancreas cancer 
     Upper GI cancer 
     Other cancers 
 
554 (71.9) 
106 (13.7) 
18 (2.3) 
5 (0.6) 
58 (7.5) 
30 (3.9) 
 
22 (64.7) 
7 (20.6) 
- 
- 
5 (14.7) 
- 
 
18 (78.3) 
3 (13.0) 
- 
- 
1 (4.3) 
1 (4.3) 
Grouped diagnosis 
     Pelvic region cancerd  
     Non-pelvic region cancere  
     Other cancers  
 
697 (90.8) 
71 (9.2) 
3 (0.4) 
 
29 (85.3) 
5 (14.7) 
- 
 
22 (95.7) 
1 (4.3) 
- 
Treatment type 
    Capecitabine 
    5-FU 
 
668 (86.6) 
103 (13.4)    
 
29 (85.3) 
5 (14.7) 
 
20 (87) 
3 (13)    
Median dose intensityf 97% 91% 61% 
Treatment date [range] [05/2006─09/2017] [02/2008─10/2014] [12/2007─08/2017] 
Radiotherapy 
     Gy: median [range] 
     Fr: median [range] 
 
50 [7.2─73.6] 
25 [4─39] 
 
50 [36─64.8] 
25 [18─36] 
 
50 [45─78] 
25 [23─39]    
DPYD carriers 
     DPYD*2A 
     DPYD*13 
     c.2846A>T 
     c.1236G>A 
     c.1236G>A homozygote 
 
- 
- 
- 
- 
- 
 
2 (5.9) 
1 (2.9) 
9 (26.5) 
20 (58.8) 
2 (5.9) 
 
11 (47.8) 
- 
1 (4.3) 
11 (47.8) 
- 
a Wild-type patients receiving standard fluoropyrimidine dosages in chemoradiation therapy; 
b DPYD variant allele carriers receiving standard fluoropyrimidine dosages in chemoradiation therapy; 
c DPYD variant allele carriers receiving initially reduced fluoropyrimidine dosages according to current 
guidelines compared with standard fluoropyrimidine dosages used in chemoradiation therapy. One DPYD*2A 
 
 
variant carrier started intravenous 5-FU therapy at a 100% dose before the genotype result became available. 
When the genotype was known, the administration of 5-FU was prematurely stopped after 2 instead of 4 days. 
In the second cycle a 50% dose reduction over 4 days was applied. The overall dose intensity of this patient 
was 49%. In three DPYD*2A carriers initial reduced dosages were increased during treatment. One patient was 
included in the clinical trial (NCT00838370) before existence of dosing guidelines and started with 30% of the 
standard total dose, which was increased to 46%. One patient went from 50 to 60% of the standard total dose 
and for another patient the dose was increased from 50 to 83%. The latter patient was excluded from 
statistical analyses, due to the substantial dose increase. The c.2846A>T variant carrier who received a dose 
reduction, was treated with a 60% dose; 
d Included are cancers of the colon sigmoidal, rectum, anus, vulva, vagina, cervix, uterus, endometrium, 
bladder, urethra, prostate and double tumours with one tumour in the pelvic area;  
e Included are cancers of the breast, stomach, oesophagus, pancreas, skin and tongue; 
f Dose intensity was calculated by dividing the received amount of mg of chemotherapy by the initial scheduled 
amount of mg of chemotherapy.  
Abbreviations: BSA: body surface area; DPYD: gene encoding dihydropyrimidine dehydrogenase; 5-FU: 5-
fluorouracil; Fr: fractions; GI: gastro-intestinal tract; Gy: gray; WT: wild-type patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Percentages of severe toxicity 
Shown are the percentages of severe gastrointestinal and severe haematological toxicity of DPYD variant allele 
carriers with and without fluoropyrimidine dose reductions and wild-type patients in chemoradiation 
treatment.  
Abbreviations: OR: adjusted odds ratio; DPYD: gene encoding dihydropyrimidine dehydrogenase; GI= 
gastrointestinal; HEM: haematological. 
Included in Table 3 are any changes applied in chemotherapy during treatment due to adverse 
events, such as dose interruptions. Compared with wild-type patients, DPYD variant allele carriers 
had more dose reductions during treatment, stopped treatment prematurely and were hospitalised 
more often, regardless of any received dose reductions. However, the mean duration of 
hospitalisation of DPYD variant allele carriers who received a dose reduction was notably shorter (4 
days) compared with the DPYD variant allele carriers treated with a standard dose (23 days, 
p=0.010). 
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Table 3. Toxicity of patients per study group 
Shown per study group are percentages of several types of (grouped) toxicity after chemoradiation therapy 
and actions following toxicity. P-values are shown for executed statistical tests. 
Type of event WT + standarda 
(N=771) 
N (%) 
DPYD + standardb 
(N=34)  
N (%) 
DPYD + reducedc  
(N=22)  
N (%) 
Grade 2 Diarrhoea 
Grade ≥3 Diarrhoea 
122 (15.8) 
58 (7.5) 
5 (14.7) 
6 (17.6) 
3 (13.6) 
2 (9.1) 
Grade 2 Mucositis  
Grade ≥3 Mucositis 
51 (6.6) 
13 (1.7) 
2 (5.9) 
- 
2 (9.1) 
- 
Grade 2 Nausead 
Grade ≥3 Nausead 
13 (4.2) 
2 (0.6) 
2 (40) 
1 (20) 
1 (6.7)  
- 
Grade 2 Vomitinge 
Grade ≥3 Vomitinge 
12 (5.4) 
1 (0.5) 
2 (66.7) 
1 (33.3) 
1 (7.1) 
- 
Grade 2 Neutropenia 
Grade ≥3 Neutropenia 
8 (1) 
12 (1.6) 
1 (2.9) 
2 (5.9) 
1 (4.5) 
2 (9.1) 
Grade 2 Leukocytopenia  
Grade ≥3 Leukocytopenia 
60 (7.8) 
17 (2.2) 
7 (20.6) 
4 (11.8) 
2 (9.1) 
2 (9.1) 
Grade 2 Thrombocytopenia  
Grade ≥3 Thrombocytopenia 
6 (0.8) 
5 (0.6) 
- 
- 
1 (4.5) 
- 
Grade 2 Anaemiad 
Grade ≥3 Anaemiad 
25 (8) 
1 (0.3) 
1 (20) 
1 (20) 
2 (13.3) 
- 
Grade 2 Radiation dermatitisd 
Grade ≥3 Radiation dermatitisd 
77 (24.7) 
13 (4.2) 
1 (20) 
- 
5 (33.3) 
- 
Grade 2 HFS  
Grade 3 HFS 
19 (2.5) 
5 (0.6) 
- 
- 
1 (4.5) 
- 
Grade 2 Cardio toxicity 
Grade ≥3 Cardio toxicity 
21 (2.7) 
11 (1.4) 
- 
- 
- 
- 
Grade 2 Fatiguee 
Grade ≥3 Fatiguee 
28 (12.6) 
2 (0.9) 
1 (33.3) 
2 (66.7) 
4 (28.6)  
- 
Grouped type of events    
Grade 2 GI toxicityf 
Grade ≥3 GI toxicityf 
138 (17.9)  
62 (8) 
5(14.7) 
6 (17.6)     p=0.045g 
6 (27.3) 
2 (9.1)    p=0.904g 
Grade 2 HEM toxicityh 
Grade ≥3 HEM toxicityh 
62 (8) 
22 (2.9) 
7 (20.6) 
4 (11.8)     p=0.015g 
2 (9.1) 
2 (9.1)    p=0.083g 
Grade 2 Overall toxicityi  
Grade ≥3 Overall toxicityi 
252 (32.7) 
105 (13.6) 
7 (20.6) 
8 (23.5) 
7 (31.8) 
5 (22.7) 
Actions    
Chemotherapy changes    
     Dose reductions  
     Dose increases 
     Interruptions 
     Prematurely stopped 
34 (4.4) 
4 (0.5) 
38 (4.9) 
76 (9.9) 
4 (11.8)j  
- 
- 
6 (17.6) 
2 (9.1)k  
2 (9.1)l  
1 (4.5) 
4 (18.2) 
Treatment-related 
hospitalization 
60 (7.8) 6 (17.6) 4 (18.2) 
Days of hospitalization, mean 
[range] 
13 [1─76] 23 [6─36] 4 [2─5]    p=0.010m 
a Wild-type patients receiving standard fluoropyrimidine dosages in chemoradiation therapy; 
b DPYD variant allele carriers receiving standard fluoropyrimidine dosages in chemoradiation therapy; 
c DPYD variant allele carriers receiving initially reduced fluoropyrimidine dosages according to current 
guidelines compared with standard fluoropyrimidine dosages used in chemoradiation therapy; 
d Data of 332 patients in total, data of 5 patients in the group of DPYD variant allele carriers treated with a 
standard dose  and data of 15 patients in the group of DPYD variant allele carriers who received dose 
reductions;  
 
 
e Data of 239 patients in total, data of 3 patients in the group of DPYD variant allele carriers treated with a 
standard dose and data of 14 patients in the group of DPYD variant allele carriers who received dose 
reductions; 
f GI toxicity includes diarrhoea, mucositis, nausea, vomiting; 
g P-values shown are compared with wild-type patients; 
h HEM toxicity includes neutropenia, thrombocytopenia, leukocytopenia; 
i Overall toxicity includes diarrhoea, mucositis, nausea, vomiting, neutropenia, thrombocytopenia, 
leukocytopenia, anaemia, radiation dermatitis, HFS, cardio toxicity, fatigue and other toxicity; 
j Dosages were reduced from 100 to 60-77%; 
k Dosages were reduced from 70 to 45% and 100 to 50% (applying dosing guidelines 2 days after start of 
therapy);  
l Dosages were increased from 30 to 46% and from 50 to 60%; 
m P-values shown are compared with DPYD variant allele carriers who received a standard dose.  
Abbreviations: DPYD: gene encoding dihydropyrimidine dehydrogenase; GI: gastrointestinal; HFS: hand-foot 
syndrome; HEM: haematological; WT: wild-type patients. 
 
Case description 
To illustrate the importance of dose reductions in DPYD variant allele carriers, we have shown the 
course of one DPYD*2A carrier in Figure 2. This patient was excluded from the statistical analyses 
due to a substantially increased dose during treatment. Being one of the first DPYD variant allele 
carriers who received 50% dosed CRT, it was decided that the fluoropyrimidine dose would be 
titrated up to 100% if the patient would have no side-effects after two weeks. However, diarrhoea 
grade 1─2 was present, and the dose was increased to 83%. After four weeks, severe toxicity 
(diarrhoea, vomiting, nausea grade 3 and dermatitis grade 2) occurred and chemotherapy, and later 
radiotherapy, was stopped prematurely. The patient was hospitalised for 31 days, of which three 
days at the intensive care unit. After hospitalisation, the patient had to recover completely from 
toxicity for 39 days in a nursing home (rehabilitation). Although it cannot be excluded that toxicity 
would have evolved in the severity as was now shown at an 83% dose level when treated entirely 
with a 50% dose level, it is clear that the dose increase was most likely a reason for the development 
of severe toxicity.   
Figure 2. Course of treatment and toxicity 
Shown is the course of an ideal treatment, and the treatment and toxicity for one patient (#1). The patient is a 
carrier of the DPYD*2A variant and started therapy on a 50% dose. After two weeks, the dose was increased to 
83%. Thereafter, the patient developed severe toxicity, and therapy was discontinued. The patient was 
hospitalised for 31 days (including three days at the intensive care unit) and had to recover completely from 
toxicity for 39 days in a nursing home (rehabilitation).  
Abbreviations: CT: chemotherapy; RT: radiotherapy.  
 
 
Discussion 
Fluoropyrimidine dosages are lower in CRT compared with other fluoropyrimidine treatment 
regimens, and it is unclear if pharmacogenetic dose adjustments should be made for DPYD variant 
allele carriers receiving CRT. Dose titration in CRT is more difficult compared with other treatment 
regimens where the schedule contains so-called stop weeks. To our knowledge, this is the first study 
specifically investigating DPYD pharmacogenetics of fluoropyrimidines in CRT. DPYD variant allele 
carriers treated with standard fluoropyrimidine dosages in CRT showed a significantly increased risk 
to develop severe toxicity compared with wild-type patients. This indicates the need for 
pharmacogenetic dose reductions in CRT, despite the lower standard dosages.  
 
Although over 800 patients are considered, the number of patients with a DPYD variant remains 
limited due to the low prevalence of DPYD variants. We were unable to show that the risk of toxicity 
in DPYD variant allele carriers who received dose reductions was equivalent to the risk of wild-type 
patients. Also, 85% of the DPYD variant allele carriers treated with a standard dose were carriers of 
the c.1236G>A and c.2846A>T variants. DPYD*2A and DPYD*13 carriers have a higher risk of toxicity 
when treated with standard dosages compared with c.1236G>A and c.2846A>T carriers. Therefore, it 
is possible that more toxicity could have occurred in this group if DPYD variants would have been 
equally distributed, increasing the difference in toxicity compared with the other study groups. 
Moreover, in the DPYD group with initial dose reductions, DPYD variants and corresponding dose 
reductions (25 versus 50%) were equally distributed.  
 
Noteworthy, the number of hospitalisations due to toxicity was similar in both groups of DPYD 
variant allele carriers, yet the duration of hospitalisation was significantly shorter in DPYD variant 
allele carriers treated with a reduced fluoropyrimidine dose. A possible explanation for this could be 
that treating physicians are alarmed of a potentially increased risk of toxicity because of DPD 
deficiency and more rapidly decide to hospitalise a patient in response to signs of potential toxicity. 
A second explanation is that DPYD variant allele carriers who received dose reductions recovered 
faster of toxicity.  
 
In two DPYD variant allele carriers who received initially reduced dosages and did not experience 
(severe) toxicity, the dose was increased during treatment. This shows that physicians might still 
have fear of underdosing patients and reducing efficacy of the treatment.  
 
Grouped diagnosis was significantly associated to severe haematological toxicity, with more severe 
toxicity in pelvic malignancies. A possible explanation may be that more bone marrow is exposed to 
radiation in the pelvic area compared with other areas, increasing the chance of myelosuppression.  
 
With over 800 patients included, this study provides a large amount of toxicity data of wild-type 
patients and DPYD variant allele carriers receiving CRT. However, our study has several limitations. 
First, three databases were combined and were partly retrospective, possibly introducing bias. 
However, each database included patients in each study group, limiting bias. General differences in 
scoring toxicity per database could exist; however, criteria for toxicity grades are well marked and 
should therefore be limited. One database used the new version of CTC-AE; however, updates did 
not influence the grading of toxicity of interest for this study.  
 
 
Second, not all databases contained the full toxicity spectrum of interest in this study (e.g. nausea, 
vomiting, radiation dermatitis, fatigue); therefore, overall toxicity consisted of different toxicities per 
original database and was not used as a primary end-point.  
And third, pharmacokinetic sampling was not executed in this study, which could have shown that 
dose reductions in DPYD variant allele carriers result in equivalent fluoropyrimidine metabolite 
plasma levels compared with wild-types treated with standard dosages, as was done previously for 
DPYD*2A variant allele carriers.19  
 
Conclusions 
Our study is the first to show that DPYD variant allele carriers have an increased risk of severe 
toxicity when treated with standard dosages in CRT, indicating that dose reductions are necessary in 
these patients as well. The present study provides the only evidence at this time, and based on these 
data we advise that fluoropyrimidine dose reductions should also be applied in DPYD variant allele 
carriers who will start CRT to prevent severe fluoropyrimidine-induced toxicity.  
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Supplementary table 1. Toxicity of study patients compared to patients from literature 
Selected studies from literature had relatively large patient cohorts and reported toxicity extensively.  
Type of event Studya (N=674) 
% 
Literature1-3 
% 
Grade 2 Diarrhoea 
Grade ≥3 Diarrhoea 
17.4 
8.6 
3─20 
2─7 
Grade 2 Nauseab 
Grade ≥3 Nauseab    
3.8 
1.1 
2─10 
- 
Grade 2 Mucositis 
Grade ≥3 Mucositis 
2.1  
0.7  
7 
- 
Grade 2 Radiation dermatitisb 
Grade ≥3  Radiation dermatitisb 
15.8 
2.3 
15─25 
0─9 
Grade 2 Fatiguec 
Grade ≥3 Fatiguec 
9.3 
1.7 
11 
2 
Grade 2 HFS 
Grade 3 HFS 
3 
0.6 
3─4 
- 
Grade 2 Neutropenia 
Grade ≥3 Neutropenia 
0.9 
0.7 
5─8 
1─2 
Grade 2 Leukocytopenia 
Grade ≥3 Leukocytopenia 
8.5 
1.6 
19─20 
1─2 
Grade 2 Thrombocytopenia 
Grade ≥3 Thrombocytopenia 
0.3 
0.3 
- 
- 
Grade 2 Anaemiab 
Grade ≥3 Anaemiab 
5.6 
0.4 
7─20 
- 
a Selected from this study are all patients with a similar capecitabine schedule to referenced locally advanced 
rectal patients from literature (825 mg/m2 twice daily, for 5 weeks with or without weekends); 
b Data of 266 patients; 
c Data of 172 patients. 
Abbreviations: HFS: hand-foot syndrome. 
  
 
 
Supplementary table 2. Toxicity of patients from three original databases and of the combined database 
(total) 
Type of event DB#1:NKI 
(N=495) 
N (%) 
DB#2:LUMC 
(N=239) 
N (%) 
DB#3:CRO 
(N=93) 
N (%) 
TOTAL 
(N=827) 
N (%) 
Grade 2 Diarrhoea 
Grade ≥3 Diarrhoea 
56 (11.3) 
43 (8.7) 
50 (20.9) 
19 (7.9) 
24 (25.8) 
4 (4.3) 
130 (15.7) 
66 (8) 
Grade 2 Mucositis  
Grade ≥3 Mucositis 
15 (3) 
3 (0.6) 
5 (2.1) 
4 (1.7) 
1 (1.1) 
- 
21 (2.5) 
7 (0.8) 
Grade 2 Nausea 
Grade ≥3 Nausea 
ND 
ND 
14 (5.9) 
3 (1.3) 
2 (2.2) 
- 
16 (4.8)a 
3 (0.9)a 
Grade 2 Vomiting 
Grade ≥3 Vomiting  
ND 
ND 
15 (6.3) 
2 (0.8) 
ND 
ND 
15 (6.3)b 
2 (0.8)b 
Grade 2 Neutropenia 
Grade ≥3 Neutropenia 
5 (1) 
10 (2) 
5 (2.1) 
5 (2.1) 
- 
1 (1.1) 
10 (1.2) 
16 (1.9) 
Grade 2 Leukocytopenia  
Grade ≥3 Leukocytopenia 
27 (5.5) 
10 (2) 
24 (10) 
7 (2.9) 
18 (19.4) 
6 (6.5) 
69 (8.3) 
23 (2.8) 
Grade 2 Thrombocytopenia  
Grade ≥3 Thrombocytopenia 
3 (0.6) 
2 (0.4) 
3 (1.3) 
3 (1.3) 
1 (1.1) 
- 
7 (0.8) 
5 (0.6) 
Grade 2 Anaemia 
Grade ≥3 Anaemia 
ND 
ND 
26 (10.9) 
2 (0.8) 
2 (2.2) 
- 
28 (8.4)a 
2 (0.6)a 
Grade 2 Radiation dermatitis  
Grade ≥3 Radiation dermatitis 
ND 
ND 
80 (33.5) 
9 (3.8) 
3 (3.2) 
4 (4.3) 
83 (25)a 
13 (3.9)a 
Grade 2 HFS  
Grade 3 HFS 
12 (2.4) 
4 (0.8) 
7 (2.9) 
1 (0.4) 
1 (1.1) 
- 
20 (2.4) 
5 (0.6) 
Grade 2 Cardio toxicity 
Grade ≥3 Cardio toxicity 
10 (2) 
5 (1) 
7 (2.9) 
1 (0.4) 
4 (4.3) 
5 (5.4) 
21 (2.5) 
11 (1.3) 
Grade 2 Fatigue 
Grade ≥3 Fatigue 
ND 
ND 
33 (13.8) 
4 (1.7) 
ND 
ND 
33 (13.8)b 
4 (1.7)b 
Grade 2 Other toxicityc 
Grade ≥3 Other toxicityc 
ND 
ND 
13 (5.4) 
7 (2.9) 
38 (40.9) 
6 (6.5) 
51 (15.4)a 
13 (3.9)a 
Grouped type of events     
Grade 2 GI toxicityd 
Grade ≥3 GI toxicityd 
67 (13.5) 
44 (8.9) 
56 (23.4) 
22 (9.2) 
26 (28) 
4 (4.3) 
149 (18) 
70 (8.5) 
Grade 2 HEM toxicitye 
Grade ≥3 HEM toxicitye 
29 (5.9) 
12 (2.4) 
24 (10) 
10 (4.2) 
18 (19.4) 
6 (6.5) 
71 (8.6) 
28 (3.4) 
Grade 2 Overall toxicityf 
Grade ≥3 Overall toxicityf 
93 (18.8) 
61 (12.3) 
118 (49.4) 
38 (15.9) 
55 (59.1) 
19 (20.4) 
266 (32.2) 
118 (14.3) 
a Data of 332 patients; 
b Data of 239 patients; 
c Other toxicity includes anal pain, chronic enteritis, cystitis (genitourinary tract), dizziness, dysgeusia, 
enterocolitis, fever, headache, multi-organ failure, papulopustular rash, proctitis, radio-enteritis, skin 
hyperpigmentation, stomatitis, thromboembolic event, ulcer of the small intestine; 
d GI toxicity includes diarrhoea, mucositis, nausea, vomiting; 
e HEM toxicity includes neutropenia, thrombocytopenia, leukocytopenia; 
f Overall toxicity includes diarrhoea, mucositis, nausea, vomiting, neutropenia, thrombocytopenia, 
leukocytopenia, anaemia, radiation dermatitis, HFS, cardio toxicity, fatigue and other toxicity. 
Abbreviations: CRO: Aviano National Cancer Institute; DB: database; GI: gastrointestinal; HFS: hand-foot 
syndrome; HEM: haematological; LUMC: Leiden University Medical Center; ND: not defined in database; NKI: 
Netherlands Cancer Institute. 
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